Journal
JOURNAL OF CLINICAL PATHOLOGY
Volume 76, Issue 1, Pages 59-63Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/jclinpath-2021-208105
Keywords
pathology; molecular; medical oncology; genes; neoplasm; genetics
Categories
Ask authors/readers for more resources
This report illustrates three potential pitfalls related to amplicon-based NGS assays and highlights strategies to minimize such risks.
Amplicon-based next-generation sequencing (NGS) assays employ highly sensitive, rapid, and cost-effective methods to detect clinically actionable mutations for the diagnosis, prognosis, and treatment of patients with cancer. However, recognition of certain limitations inherent to amplicon-based NGS assays is crucial for the correct interpretation and reporting of variants in the clinical setting. In this report, we illustrate three different potential pitfalls related to amplicon-based NGS assays based on our institutional experience and highlight how the risk of such events can be minimised.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available